Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma

Adil I. Daud, Jedd D. Wolchok, Caroline Robert, Wen Jen Hwu, Jeffrey S. Weber, Antoni Ribas, F. Stephen Hodi, Anthony M. Joshua, Richard Kefford, Peter Hersey, Richard W Joseph, Tara C. Gangadhar, Roxana S Dronca, Amita Patnaik, Hassane Zarour, Charlotte Roach, Grant Toland, Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth EmancipatorMarisa Dolled-Filhart, S. Peter Kang, Scot Ebbinghaus, Omid Hamid

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

Purpose: Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1). This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods: Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks. Tumor response was assessed every 12 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent central review. Primary outcome was objective response rate. Secondary outcomes included progression-free survival (PFS) and overall survival (OS). Membranous PD-L1 expression in tumor and tumor-associated immune cells was assessed by a clinical trial immunohistochemistry assay (22C3 antibody) and scored on a unique melanoma (MEL) scale of 0 to 5 by one of three pathologists who were blinded to clinical outcome; a score ≥ 2 (membranous staining in ≥ 1% of cells) was considered positive. Results: Of 451 patients with evaluable PD-L1 expression, 344 (76%) had PD-L1-positive tumors. Demographic and staging variables were equally distributed among PD-L1-positive and -negative patients. An association between higher MEL score and higher response rate and longer PFS (hazard ratio, 0.76; 95% CI, 0.71 to 0.82) and OS (hazard ratio, 0.76; 95% CI, 0.69 to 0.83) was observed (P < .001 for each). Objective response rate was 8%, 12%, 22%, 43%, 57%, and 53% for MEL 0, 1, 2, 3, 4, and 5, respectively. Conclusion: PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-negative tumors may also achieve durable responses.

Original languageEnglish (US)
Pages (from-to)4102-4109
Number of pages8
JournalJournal of Clinical Oncology
Volume34
Issue number34
DOIs
StatePublished - Dec 1 2016

Fingerprint

Melanoma
Ligands
Antibodies
Disease-Free Survival
Neoplasms
Survival
pembrolizumab
Clinical Trials
Immunohistochemistry
Demography
Staining and Labeling
Biopsy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W. J., Weber, J. S., Ribas, A., ... Hamid, O. (2016). Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. Journal of Clinical Oncology, 34(34), 4102-4109. https://doi.org/10.1200/JCO.2016.67.2477

Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. / Daud, Adil I.; Wolchok, Jedd D.; Robert, Caroline; Hwu, Wen Jen; Weber, Jeffrey S.; Ribas, Antoni; Hodi, F. Stephen; Joshua, Anthony M.; Kefford, Richard; Hersey, Peter; Joseph, Richard W; Gangadhar, Tara C.; Dronca, Roxana S; Patnaik, Amita; Zarour, Hassane; Roach, Charlotte; Toland, Grant; Lunceford, Jared K.; Li, Xiaoyun Nicole; Emancipator, Kenneth; Dolled-Filhart, Marisa; Kang, S. Peter; Ebbinghaus, Scot; Hamid, Omid.

In: Journal of Clinical Oncology, Vol. 34, No. 34, 01.12.2016, p. 4102-4109.

Research output: Contribution to journalArticle

Daud, AI, Wolchok, JD, Robert, C, Hwu, WJ, Weber, JS, Ribas, A, Hodi, FS, Joshua, AM, Kefford, R, Hersey, P, Joseph, RW, Gangadhar, TC, Dronca, RS, Patnaik, A, Zarour, H, Roach, C, Toland, G, Lunceford, JK, Li, XN, Emancipator, K, Dolled-Filhart, M, Kang, SP, Ebbinghaus, S & Hamid, O 2016, 'Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma', Journal of Clinical Oncology, vol. 34, no. 34, pp. 4102-4109. https://doi.org/10.1200/JCO.2016.67.2477
Daud, Adil I. ; Wolchok, Jedd D. ; Robert, Caroline ; Hwu, Wen Jen ; Weber, Jeffrey S. ; Ribas, Antoni ; Hodi, F. Stephen ; Joshua, Anthony M. ; Kefford, Richard ; Hersey, Peter ; Joseph, Richard W ; Gangadhar, Tara C. ; Dronca, Roxana S ; Patnaik, Amita ; Zarour, Hassane ; Roach, Charlotte ; Toland, Grant ; Lunceford, Jared K. ; Li, Xiaoyun Nicole ; Emancipator, Kenneth ; Dolled-Filhart, Marisa ; Kang, S. Peter ; Ebbinghaus, Scot ; Hamid, Omid. / Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 34. pp. 4102-4109.
@article{06aa6c0f1c1d49b38585b9ea2f5f9f42,
title = "Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma",
abstract = "Purpose: Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1). This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods: Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks. Tumor response was assessed every 12 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent central review. Primary outcome was objective response rate. Secondary outcomes included progression-free survival (PFS) and overall survival (OS). Membranous PD-L1 expression in tumor and tumor-associated immune cells was assessed by a clinical trial immunohistochemistry assay (22C3 antibody) and scored on a unique melanoma (MEL) scale of 0 to 5 by one of three pathologists who were blinded to clinical outcome; a score ≥ 2 (membranous staining in ≥ 1{\%} of cells) was considered positive. Results: Of 451 patients with evaluable PD-L1 expression, 344 (76{\%}) had PD-L1-positive tumors. Demographic and staging variables were equally distributed among PD-L1-positive and -negative patients. An association between higher MEL score and higher response rate and longer PFS (hazard ratio, 0.76; 95{\%} CI, 0.71 to 0.82) and OS (hazard ratio, 0.76; 95{\%} CI, 0.69 to 0.83) was observed (P < .001 for each). Objective response rate was 8{\%}, 12{\%}, 22{\%}, 43{\%}, 57{\%}, and 53{\%} for MEL 0, 1, 2, 3, 4, and 5, respectively. Conclusion: PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-negative tumors may also achieve durable responses.",
author = "Daud, {Adil I.} and Wolchok, {Jedd D.} and Caroline Robert and Hwu, {Wen Jen} and Weber, {Jeffrey S.} and Antoni Ribas and Hodi, {F. Stephen} and Joshua, {Anthony M.} and Richard Kefford and Peter Hersey and Joseph, {Richard W} and Gangadhar, {Tara C.} and Dronca, {Roxana S} and Amita Patnaik and Hassane Zarour and Charlotte Roach and Grant Toland and Lunceford, {Jared K.} and Li, {Xiaoyun Nicole} and Kenneth Emancipator and Marisa Dolled-Filhart and Kang, {S. Peter} and Scot Ebbinghaus and Omid Hamid",
year = "2016",
month = "12",
day = "1",
doi = "10.1200/JCO.2016.67.2477",
language = "English (US)",
volume = "34",
pages = "4102--4109",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "34",

}

TY - JOUR

T1 - Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma

AU - Daud, Adil I.

AU - Wolchok, Jedd D.

AU - Robert, Caroline

AU - Hwu, Wen Jen

AU - Weber, Jeffrey S.

AU - Ribas, Antoni

AU - Hodi, F. Stephen

AU - Joshua, Anthony M.

AU - Kefford, Richard

AU - Hersey, Peter

AU - Joseph, Richard W

AU - Gangadhar, Tara C.

AU - Dronca, Roxana S

AU - Patnaik, Amita

AU - Zarour, Hassane

AU - Roach, Charlotte

AU - Toland, Grant

AU - Lunceford, Jared K.

AU - Li, Xiaoyun Nicole

AU - Emancipator, Kenneth

AU - Dolled-Filhart, Marisa

AU - Kang, S. Peter

AU - Ebbinghaus, Scot

AU - Hamid, Omid

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Purpose: Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1). This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods: Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks. Tumor response was assessed every 12 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent central review. Primary outcome was objective response rate. Secondary outcomes included progression-free survival (PFS) and overall survival (OS). Membranous PD-L1 expression in tumor and tumor-associated immune cells was assessed by a clinical trial immunohistochemistry assay (22C3 antibody) and scored on a unique melanoma (MEL) scale of 0 to 5 by one of three pathologists who were blinded to clinical outcome; a score ≥ 2 (membranous staining in ≥ 1% of cells) was considered positive. Results: Of 451 patients with evaluable PD-L1 expression, 344 (76%) had PD-L1-positive tumors. Demographic and staging variables were equally distributed among PD-L1-positive and -negative patients. An association between higher MEL score and higher response rate and longer PFS (hazard ratio, 0.76; 95% CI, 0.71 to 0.82) and OS (hazard ratio, 0.76; 95% CI, 0.69 to 0.83) was observed (P < .001 for each). Objective response rate was 8%, 12%, 22%, 43%, 57%, and 53% for MEL 0, 1, 2, 3, 4, and 5, respectively. Conclusion: PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-negative tumors may also achieve durable responses.

AB - Purpose: Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1). This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods: Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks. Tumor response was assessed every 12 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent central review. Primary outcome was objective response rate. Secondary outcomes included progression-free survival (PFS) and overall survival (OS). Membranous PD-L1 expression in tumor and tumor-associated immune cells was assessed by a clinical trial immunohistochemistry assay (22C3 antibody) and scored on a unique melanoma (MEL) scale of 0 to 5 by one of three pathologists who were blinded to clinical outcome; a score ≥ 2 (membranous staining in ≥ 1% of cells) was considered positive. Results: Of 451 patients with evaluable PD-L1 expression, 344 (76%) had PD-L1-positive tumors. Demographic and staging variables were equally distributed among PD-L1-positive and -negative patients. An association between higher MEL score and higher response rate and longer PFS (hazard ratio, 0.76; 95% CI, 0.71 to 0.82) and OS (hazard ratio, 0.76; 95% CI, 0.69 to 0.83) was observed (P < .001 for each). Objective response rate was 8%, 12%, 22%, 43%, 57%, and 53% for MEL 0, 1, 2, 3, 4, and 5, respectively. Conclusion: PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-negative tumors may also achieve durable responses.

UR - http://www.scopus.com/inward/record.url?scp=84995890821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995890821&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.67.2477

DO - 10.1200/JCO.2016.67.2477

M3 - Article

C2 - 27863197

AN - SCOPUS:84995890821

VL - 34

SP - 4102

EP - 4109

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 34

ER -